Andrew Fraley, a founder of Korro Bio, serves as SVP of Technology. Andrew brings over 20 years of experience in the field of nucleic acid technologies and therapeutics. A scientist and entrepreneur at heart, he has founded biotech companies including Triplet Therapeutics, Korro Bio and Trucode Gene Repair, and additionally functions as an Entrepreneur for Atlas Venture. Prior to Korro, Andrew was a commercial founder and served as SVP of Translational Sciences for a Trucode Gene Repair, an in vivo gene-editing company, leading the company’s scientific strategy and operations.
Dr. Fraley has authored and reviewed scientific publications and is listed as an inventor on patents in areas including nucleic acid therapeutics, oligonucleotide delivery, and macrocyclic drug discovery. He holds a B.A. from DePauw University, earned his Ph.D. in Bioorganic Chemistry at Boston College, and was a Chateaubriand Postdoctoral Research Fellow at the Louis Pasteur University.